DOCSLIB.ORG

Characterization of Monoclonal Antibody Epitope Specificity Using Biacore’S SPR Technology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Characterization of Monoclonal Antibody Epitope Specificity Using Biacore’S SPR Technology APPLICATION NOTE 1 Characterization of monoclonal antibody epitope specificity using Biacore’s SPR technology Abstract Biacore’s SPR technology based on surface plasmon resonance technology has been used to map the epitope specificity patterns of 30 monoclonal antibodies against recombinant HIV-1 core protein p24. The technique does not require labelling of either antibodies or antigen, and all specificity determinations were performed with antibodies in unfractionated hybridoma culture supernatants. Pair-wise binding tests divided the 30 antibodies into 17 groups, representing 17 epitopes on the antigen. Introduction Epitope mapping using monoclonal antibodies (MAbs) is a powerful tool in examining the surface topography of macromolecules. Through its binding, each MAb defines one specific site, or epitope, on the antigen, and a pair of MAbs which bind to closely situated epitopes will interfere sterically with each other’s binding [1,2,3]. Determination of epitope specificity is an important part of MAb characterization for both investigative work and medical and industrial applications. The epitope specificity of a panel of MAbs is most easily determined by testing the ability of pairs of MAbs to bind simultaneously to the antigen. MAbs directed against separate epitopes will bind independently of each other, whereas MAbs directed against closely related epitopes will interfere with each other’s binding. The most common technique for determining epitope specificities tests pair-wise binding with RIA or ELISA [4]. One antibody is attached to a solid substrate, the antigen is bound, and the ability of the second antibody to bind to the surface- attached complex is tested. A drawback with these methods is that the secondary interactant must be labelled in some way. Simultaneous binding, indicating distinct epitopes, is readily identified, but it is generally more difficult to interpret an absence of simultaneous binding. This Application Note describes the characterization of epitope specificity patterns of 30 different MAbs directed against recombinant HIV-1 core protein p24. Biacore’s SPR technology [5,6] based on surface plasmon resonance (SPR) [7,8] is used to measure binding of macromolecular components to each other at a sensor chip surface. The principle of the specificity deter- SPR response is measured in resonance mination is the same as that described units (RU). For most proteins, 1000 RU for RIA- or ELISA-based techniques, but corresponds to a surface concentration of the use of SPR offers several important approximately 1 ng/mm2 [9]. advantages: Immobilization of RAMG1 on the • None of the interacting components sensor chip needs to be purified or labelled in any RAMG1 was covalently coupled to a way. As a result, the mapping can be Sensor Chip CM5 via primary amine performed using small amounts of groups using the conditions listed in Table unfractionated MAbs in cell culture 1. The resulting sensorgram (Figure 1) supernatants. shows that RAMG1 corresponding to • A mass-dependent SPR response is about 12000 RU is covalently linked to the obtained from the binding of each sensor chip surface. component to the sensor surface [9]. All stages in the binding process can Pair-wise binding of MAbs thus be monitored. Pair-wise binding of MAbs to p24 was • Each stage of the binding sequence is tested using the conditions shown in Table easily quantified, aiding the interpret- 2. Each analysis cycle concludes with ation of the results. removal of all non-covalently bound • The technique allows multi-site material from the sensor chip surface, specificity tests using a sequence of regenerating the surface in preparation for several MAbs. a new cycle. One cycle takes approximately • The average assay time is short (15 15 minutes to perform and in this example, minutes), and large numbers of analyses 60 cycles were run automatically. can be processed automatically. Materials and methods Materials SPR measurements were performed using a Biacore® system. Sensor Chip CM5 and Amine Coupling Kit for immobilization were from Biacore AB. Immunosorbent purified rabbit anti-mouse IgG1 (RAMG1), hybridoma culture supernatants containing murine MAbs against recombinant HIV-1 p24, and monoclonal anti-human alpha-fetoprotein (a-AFP) were obtained from Pharmacia Diagnostics AB, Uppsala. Recombinant HIV-1 core protein p24 was supplied by Pharmacia Genetic Engineering Inc., San Diego. Reagents HBS-EP buffer: 10 mM HEPES pH 7.4, 150 mM NaCl, 3.4 mM EDTA, 0.005% Surfactant P20 NHS: 100 mM N-hydroxysuccinimide in H2O EDC: 400 mM 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide in H2O RAMG1: RAMG1, 30 µg/ml in 10 mM Na-acetate pH 5.0 Ethanolamine: 1 M ethanolamine hydrochloride, adjusted to pH 8.5 Table 1 with NaOH Procedure for immobilizing RAMG1 on a Sensor Chip HCl: 100 mM HCl CM5, to make a specific surface for adsorption of MAbs from hybridoma supernatants. Biacore immobilization protocol Buffer flow is maintained at 0 min HBS-EP, flow 5 µl/min Start cycle 5 µl/min throughout the immobilization protocol. 5 min Mix NHS + EDC 1:1 Activate surface Inject 30 µl 11 min Inject 30 µl RAMG1 Couple RAMG1 19 min Inject 30 µl ethanolamine Deactivate excess reactive groups 26 min Inject 15 µl HCl Remove non-covalently bound material 30 min –– End cycle Figure 1 Sensorgram obtained from immobilization of RAMG1 on a Sensor Chip CM5. Numbers on the sensorgram indicate injections as follows: (1) NHS/EDC, (2) RAMG1, (3) ethanolamine, (4) HCl. Note that the SPR signal is off scale at the top of the RAMG1 peak, while the RAMG1 solution is in contact with the sensor chip. Reagents HBS-EP buffer: 10 mM HEPES pH 7.4, 150 mM NaCl, 3.4 mM EDTA, 0.005% Surfactant P20 Salt-free HBS: HBS with NaCl omitted First MAb: Undiluted hybridoma supernatant containing first MAb Blocking Ab: α-AFP, 50 µg/ml in salt-free HBS p24: p24, 10 µg/ml in 10 mM Na-acetate, pH 5.0 Table 2 Procedure for testing Second MAb: Undiluted hybridoma supernatant containing second simultaneous binding of MAb two MAbs to p24. Buffer flow HCl: 100 mM HCl is maintained at 5 µl/min throughout the analysis protocol. Biacore analysis protocol 0 min HBS-EP, flow 5 µl/min Start cycle 1 min Inject 4 µl first MAb Bind to RAMG1 4 min Inject 4 µl blocking Ab Block free RAMG1 sites 7 min Inject 4 µl p24 Bind antigen to first MAb 9.5 min Inject 4 µl second MAb Test binding 13 min Inject 10 µl HCl Regenerate surface 15 min –– End cycle Figure 2 Example of a sensorgram obtained from epitope specificity determination for two MAbs directed against independent epitopes. The SPR response gives the amount of surface-bound component at each stage as follows: (A) baseline signal, (B)-(A) first MAb, (C)-(B) blocking antibody, (D)-(C) p24, (E)-(D) second MAb. Results Figure 2 shows a typical sensorgram from tests were run only when a negative result pair-wise epitope specificity studies. The was obtained, to ensure that the absence of MAbs tested show simultaneous binding, binding was not an artefact of the sequence and are therefore judged to bind to of attachment. The final complete mapping independent epitopes. analyzed 537 binding tests, of which 185 It is essential that unoccupied RAMG1 were reciprocal duplicates with the same sites on the sensor chip surface are blocked antibodies in reversed order. before injection of the second MAb super- Four of the MAbs gave negative results natant, to avoid false positive responses. when used as the first antibody, regardless This is assured by using a concentration of of which MAb was tested as the second blocking antibody sufficient to saturate the antibody. Closer examination of the surface even in the absence of the first sensorgrams showed that these MAbs lost MAb. Although different first MAbs the ability to bind antigen when they were bound to different extents, the SPR signal attached to the surface through RAMG1, level reached after injection of the blocking although positive binding was seen in MAb was the same regardless of the many cases when these MAbs were used as amount of first MAb bound. This confirms second antibody. that the first MAb and blocking antibody These observations illustrate two together occupy all the available sites. particularly valuable features of Biacore’s Two kinds of control experiment ensure SPR technology in comparison with other that the second MAb binds to the antigen epitope mapping techniques: the reason for and not to the RAMG1 or another the negative response (lack of antigen component on the sensor chip surface: binding) is directly apparent from the • Omission of p24 from the normal assay sensorgram, and reversed-order pair-wise sequence reduces the response from the tests are easily performed. second MAb supernatant to background The reactivity patterns for the MAbs tested levels. For each supernatant, the mean are shown as a 30x30 matrix in Figure 3. background obtained with four arbitrarily chosen first MAbs was subtracted from all responses (typical background levels are 30-100 RU). • Binding of both purified MAb and p24 is eliminated if blocking antibody is injected before the first MAb. This also shows that exchange between surface- bound blocking antibody and MAb in free solution is negligible on the time scale of one assay cycle. Figure 3 In all, the epitope specificity of 30 different Reactivity pattern matrix showing the binding MAbs was characterized. Theoretically, ability of pairs of MAbs this requires 900 tests for the complete to p24. map if all pairs are to be tested in both binding sequences. In practice, however, many of the pairs will be redundant, since a positive result in the first sequence tested indicates distinct epitopes. Reciprocal pair Grouping MAbs that show the same reactivity pattern gives 17 groups representing epitopes (Figure 4), which Figure 4 may be visualized in a two-dimensional Grouping 30 MAbs according to their ‘‘surface-like’’ map shown in Figure 5.
Load more

Recommended publications
  • "Epitope Mapping: B-Cell Epitopes". In: Encyclopedia of Life Sciences
    Epitope Mapping: B-cell Advanced article Epitopes Article Contents . Introduction GE Morris, Wolfson Centre for Inherited Neuromuscular Disease RJAH Orthopaedic Hospital, . What Is a B-cell Epitope? . Epitope Mapping Methods Oswestry, UK and Keele University, Keele, Staffordshire, UK . Applications Immunoglobulin molecules are folded to present a surface structure complementary to doi: 10.1002/9780470015902.a0002624.pub2 a surface feature on the antigen – the epitope is this feature of the antigen. Epitope mapping is the process of locating the antibody-binding site on the antigen, although the term is also applied more broadly to receptor–ligand interactions unrelated to the immune system. Introduction formed of highly convoluted peptide chains, so that resi- dues that lie close together on the protein surface are often Immunoglobulin molecules are folded in a way that as- far apart in the amino acid sequence (Barlow et al., 1986). sembles sequences from the variable regions of both the Consequently, most epitopes on native, globular proteins heavy and light chains into a surface feature (comprised of are conformation-dependent and they disappear if the up to six complementarity-determining regions (CDRs)) protein is denatured or fragmented. Sometimes, by acci- that is complementary in shape to a surface structure on the dent or design, antibodies are produced against linear antigen. These two surface features, the ‘paratope’ on the (sequential) epitopes that survive denaturation, though antibody and the ‘epitope’ on the antigen, may have a cer- such antibodies usually fail to recognize the native protein. tain amount of flexibility to allow an ‘induced fit’ between The simplest way to find out whether an epitope is confor- them.
    [Show full text]
  • Epstein-Barr Virus Epitope-Major Histocompatibility Complex
    University of Massachusetts Medical School eScholarship@UMMS Open Access Articles Open Access Publications by UMMS Authors 2020-03-17 Epstein-Barr Virus Epitope-Major Histocompatibility Complex Interaction Combined with Convergent Recombination Drives Selection of Diverse T Cell Receptor alpha and beta Repertoires Anna Gil University of Massachusetts Medical School Et al. Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/oapubs Part of the Hemic and Lymphatic Diseases Commons, Immune System Diseases Commons, Immunology and Infectious Disease Commons, Infectious Disease Commons, Microbiology Commons, Virus Diseases Commons, and the Viruses Commons Repository Citation Gil A, Kamga L, Chirravuri-Venkata R, Aslan N, Clark FG, Ghersi D, Luzuriaga K, Selin LK. (2020). Epstein- Barr Virus Epitope-Major Histocompatibility Complex Interaction Combined with Convergent Recombination Drives Selection of Diverse T Cell Receptor alpha and beta Repertoires. Open Access Articles. https://doi.org/10.1128/mBio.00250-20. Retrieved from https://escholarship.umassmed.edu/ oapubs/4191 Creative Commons License This work is licensed under a Creative Commons Attribution 4.0 License. This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. RESEARCH ARTICLE Host-Microbe Biology crossm Epstein-Barr Virus Epitope–Major Histocompatibility Complex Interaction Combined with Convergent Recombination Drives Downloaded from Selection of Diverse T Cell Receptor ␣ and ␤ Repertoires Anna Gil,a Larisa Kamga,b Ramakanth Chirravuri-Venkata,c Nuray Aslan,a Fransenio Clark,a Dario Ghersi,c Katherine Luzuriaga,b Liisa K.
    [Show full text]
  • Epitope Spreading: Lessons from Autoimmune Skin Diseases
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector REVIEW Epitope Spreading: Lessons From Autoimmune Skin Diseases Lawrence S. Chan,*† Carol J. Vanderlugt,‡ Takashi Hashimoto,§ Takeji Nishikawa,¶ John J. Zone,** Martin M. Black,†† Fenella Wojnarowska,‡‡ Seth R. Stevens,§§ Mei Chen,† Janet A. Fairley,¶¶ David T. Woodley,*† Stephen D. Miller,‡ and Kenneth B. Gordon†‡ *Medicine Service, Section of Dermatology, Lakeside Division, VA Chicago Health Care System, Chicago, Illinois, U.S.A.; Departments of †Dermatology and ‡Microbiology and Immunology, Northwestern University Medical School, Chicago, Illinois, U.S.A.; ¶¶Department of Dermatology, Kurume University School of Medicine, Kurume, Japan; ¶Department of Dermatology, Keio University School of Medicine, Tokyo, Japan; **Medicine Service, Section of Dermatology, Salt Lake City VA Medical Center, Salt Lake City, Utah, U.S.A.; ††Department of Dermatopathology, Guy’s and St. Thomas Medical and Dental School, London, U.K.; ‡‡Department of Dermatology, The Oxford Radcliffe Hospital, Oxford, U.K.; §§Department of Dermatology, Case Western Reserve University School of Medicine, Cleveland, Ohio, U.S.A.; ¶¶Department of Dermatology, Medical College of Wisconsin, Milwaukee, Wisconsin, U.S.A. Autoimmune diseases are initiated when patients develop In experimental autoimmune animal diseases, ‘‘epitope aberrant T and/or B cell responses against self proteins. spreading’’ seems to have significant physiologic impor- These responses
    [Show full text]
  • Ige – the Main Player of Food Allergy
    DDMOD-431; No of Pages 8 Vol. xxx, No. xx 2016 Drug Discovery Today: Disease Models Editors-in-Chief Jan Tornell – AstraZeneca, Sweden DRUG DISCOVERY Andrew McCulloch – University of California, SanDiego, USA TODAY DISEASE MODELS IgE – the main player of food allergy 1 2,3 2 Henrike C.H. Broekman , Thomas Eiwegger , Julia Upton , 4, Katrine L. Bøgh * 1 Department of Dermatology/Allergology, University Medical Centre Utrecht (UMCU), Utrecht, The Netherlands 2 Division of Immunology and Allergy, Food Allergy and Anaphylaxis Program, The Department of Paediatrics, Hospital for Sick Children, Toronto, Canada 3 Research Institute, Physiology and Experimental Medicine, The University of Toronto, Toronto, Canada 4 National Food Institute, Technical University of Denmark, Søborg, Denmark Food allergy is a growing problem worldwide, presently Section editor: affecting 2–4% of adults and 5–8% of young children. IgE Michelle Epstein – Medical University of Vienna, is a key player in food allergy. Consequently huge Department of Dermatology, DIAID, Experimental Allergy, Waehringer Guertel 18-20, Room 4P9.02, A1090, efforts have been made to develop tests to detect Vienna, Austria. either the presence of IgE molecules, their allergen binding sites or their functionality, in order to provide allergen ingestion [1], and involve one or more of the follow- information regarding the patient’s food allergy. The ing systems; the skin (pruritus, urticaria, or angioedema), the ultimate goal is to develop tools that are capable of gastro-intestinal tract (diarrhea, vomiting, contractions, in- creased bowel movement), the respiratory tract (asthma at- discriminating between asymptomatic sensitization tack, hoarseness, stridor/laryngeal angioedema) or the and a clinically relevant food allergy, and between cardiovascular system (dizziness, drop in blood pressure, loss different allergic phenotypes in an accurate and trust- of consciousness) [2,3].
    [Show full text]
  • Protein Epitope Mapping by Mass Spectrometry
    Anal. Chem. 1994,66, 3723-3726 Protein Epitope Mapping By Mass Spectrometry Ylngmlng Zhao and Brian T. Chalt’ The Rockefeller University, 1230 York Avenue, New York, New York 10021 A mass spectrometricmethod is described for the rapid mapping antigen bound to an antibody. Alternatively, these workers of linear epitopes in proteins that are bound by monoclonal subjected the peptide to proteolytic digestion and identified antibodies. The method consists of three steps. In the first products that bound to the immobilized antibody. In both step, an antigen protein is digested by a proteolytic enzyme to cases, the peptides of interest were identified by 2Wfplasma produce an appropriate set of peptide fragments. In the second desorption mass spectrometry. step, peptide fragments containing the linear epitope are selected Matrix-assisted laser desorption mass spectrometry (MAL- and separated from the pool of peptide fragments by immu- DI-MS) is a recently developed method for measuring the noprecipitation with the monoclonal antibody. In the final molecular weights of peptides and proteins.12-14 The technique step, the immunoprecipitated peptides are identified by matrix- allows the accurate (better than O.l%), rapid (<1 min), and assisted laser desorption mass spectrometry. The method sensitive (<1 pmol) determination of the molecular weights allows the rapid determination of antigenic sites without tedious of components of complex mixtures of peptides. MALDI- peptide synthesis or protein mutagenesis. The approach is MS is finding wide use for the rapid identification of proteins demonstrated through the mapping of epitopes in two peptides and the elucidation of their primary structures (in particular, (melittin and glucagon-like peptide-1 7-37) against which the definition of posttranslational modifications.) monoclonal antibodies were raised.
    [Show full text]
  • ENCODE DCC Antibody Validation Document
    ENCODE DCC Antibody Validation Document Date of Submission Name: Email: Lab Antibody Name: Target: Company/ Source: Catalog Number, database ID, laboratory Lot Number Antibody Description: Target Description: Species Target Species Host Validation Method #1 Validation Method #2 Purification Polyclonal/ Method Monoclonal Vendor URL: Reference (PI/ Publication Information) Please complete the following for antibodies to histone modifications: if your specifications are not listed in the drop-down box, please write-in the appropriate information Histone Name AA modified AA Position Modification Validation #1 Analysis Insert Validation Image (click here) ARID3A (NB100-279) & (sc-8821) Immunoblot / Immunoprecipitation A. MW (kD) B. MW (kD) C. MW (kD) D. MW (kD) 150 150 150 150 100 100 100 100 75 75 75 75 50 50 50 50 38 38 38 38 25 25 25 20 20 20 25 15 15 15 15 Lane : 1 2 3 4 Lane : 1 2 3 Lane : 1 2 Lane : 1 2 3 A. Western Blot using NB100-279 on nuclear lysates from cell lines GM12878 (Lane1), K562 (Lane2), HeLaS3 (Lane3), and HepG2 (Lane4). B. Immunoprecipitation was performed on nuclear lysates from K562 cells using antibody NB100-279. Lane1: Nuclear lysate. Lane 3: Bound material from control immunoprecipitation with rabbit IgG. Lane 2: Bound material from immunoprecipitation with NB100-279. C. Western Blot using sc-8821 on nuclear lysates from cell lines GM12878 (Lane1), K562 (Lane2). D. Immunoprecipitation was performed on nuclear lysates from K562 cells using antibody sc-8821 and immunoblot with NB100-279. Lane1: Nuclear lysate. Lane 2: Bound material from immunoprecipitation with sc-8821. Lane 3: Bound material from control immunoprecipitation with Goat IgG.
    [Show full text]
  • A Murine CD8+ T Cell Epitope Identified in the Receptor-Binding
    Article A Murine CD8+ T Cell Epitope Identified in the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein Jihyun Yang 1,† , Eunjin Kim 1,2,†, Jong-Soo Lee 2 and Haryoung Poo 1,* 1 Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Korea; [email protected] (J.Y.); [email protected] (E.K.) 2 Department of Preventive Veterinary Medicine, College of Veterinary Medicine, Chungnam National University, Daejeon 34134, Korea; [email protected] * Correspondence: [email protected]; Tel.: +82-42-860-4157 † These authors contributed equally to this study. Abstract: The ongoing COVID-19 pandemic caused by SARS-CoV-2 has posed a devastating threat worldwide. The receptor-binding domain (RBD) of the spike protein is one of the most important antigens for SARS-CoV-2 vaccines, while the analysis of CD8 cytotoxic T lymphocyte activity in preclinical studies using mouse models is critical for evaluating vaccine efficacy. Here, we immunized C57BL/6 wild-type mice and transgenic mice expressing human angiotensin-converting enzyme 2 (ACE2) with the SARS-CoV-2 RBD protein to evaluate the IFN-γ-producing T cells in the splenocytes of the immunized mice using an overlapping peptide pool by an enzyme-linked immunospot assay and flow cytometry. We identified SARS-CoV-2 S395–404 as a major histocompatibility complex (MHC) class I-restricted epitope for the RBD-specific CD8 T cell responses in C57BL/6 mice. Keywords: SARS-CoV-2; cell-mediated immunity; CD8 cytotoxic T lymphocyte; epitope; vaccine Citation: Yang, J.; Kim, E.; Lee, J.-S.; Poo, H.
    [Show full text]
  • Epitope Mapping of an Uncertain Endogenous Antigen Implies Secretogranin II Peptide Splicing [Version 2; Peer Review: 1 Approved, 2 Approved with Reservations]
    F1000Research 2019, 8:1732 Last updated: 26 JUL 2021 RESEARCH ARTICLE Epitope mapping of an uncertain endogenous antigen implies secretogranin II peptide splicing [version 2; peer review: 1 approved, 2 approved with reservations] David R. Howlett 1, Iain J. Clarke2, Russell P. Newton3, John E. Hart4 1Wolfson Centre for Age Related Disease, Kings College London, London, SE1 1UL, UK 2School of Agriculture and Veterinary Science, Melbourne University, Parkville, Victoria, VIC 3010, Australia 3Biochemistry Group, Institute of Life Sciences, Medical School, Swansea University, Swansea, Wales, SA2 8PP, UK 4Endocrine Pharmaceuticals Ltd, Tadley, Hampshire, RG26 3TA, UK v2 First published: 09 Oct 2019, 8:1732 Open Peer Review https://doi.org/10.12688/f1000research.20633.1 Latest published: 05 Dec 2019, 8:1732 https://doi.org/10.12688/f1000research.20633.2 Reviewer Status Invited Reviewers Abstract Background: The search for a tissue-mass reducing reproductive 1 2 3 hormone involved a bioassay-guided physicochemical fractionation of sheep blood plasma. This brought forth a candidate protein whose version 2 apparent mass on gels and in mass spectrometry (MS) was 7-8 kDa, (revision) report report implying a polypeptide of ~70 residues. Four purification runs gave 05 Dec 2019 Edman N-terminal sequences relating to 1MKPLTGKVKEFNNI14. This is bioinformatically obscure and has been resistant to molecular version 1 biological investigation. The sequence was synthesized as the peptide 09 Oct 2019 report report EPL001, against which was raised a goat polyclonal antiserum, G530. Used in an antigen capture campaign, G530 pointed to the existence of a novel derivative of secretogranin II (SgII), the neuroendocrine 1.
    [Show full text]
  • Highly Accurate and Reproducible Diagnosis of Peanut Allergy Using Epitope Mapping
    medRxiv preprint doi: https://doi.org/10.1101/2020.06.19.20136002; this version posted June 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Highly Accurate and Reproducible Diagnosis of Peanut Allergy Using Epitope Mapping Paul Kearney1, Robert Getts1, Clive Hayward1, David Luta1, Alex Porter1, Marc Witmer1, George du Toit2, Gideon Lack2, R. Sharon Chinthrajah3, Stephen J Galli3,4, Kari Nadeau3, Galina Grishina5, Mayte Suárez-Fariñas5, Maria Suprun5, Hugh A Sampson5 1. AllerGenis LLC, Hatfield, PA, USA 2. King’s College London, London, UK 3. Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, USA 4. Departments of Pathology and Microbiology & Immunology, Stanford University. 5. Department of Pediatrics, Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, USA Abstract Background: Misdiagnosis of peanut allergy is a significant clinical challenge. Here, a novel diagnostic blood-based test using a Bead-Based Epitope Assay (“peanut BBEA”) has been developed on the LEAP cohort and then independently validated on the CoFAR2 and POISED cohorts. Methods: Development of the peanut BBEA followed the National Academy of Medicine’s established guidelines with discovery performed on 133 subjects from the non- interventional arm of the LEAP trial and an independent validation performed on 81 subjects from the CoFAR2 study and 84 subjects from the POISED study. All subject samples were analyzed using the BBEA methodology.
    [Show full text]
  • Heteroclitic CD8 T Cell Epitopes Enhanced Antiviral Immunity
    Structural and Functional Correlates of Enhanced Antiviral Immunity Generated by Heteroclitic CD8 T Cell Epitopes This information is current as Jonathan A. Trujillo, Stephanie Gras, Kelly-Anne Twist, of September 30, 2021. Nathan P. Croft, Rudragouda Channappanavar, Jamie Rossjohn, Anthony W. Purcell and Stanley Perlman J Immunol 2014; 192:5245-5256; Prepublished online 2 May 2014; doi: 10.4049/jimmunol.1400111 Downloaded from http://www.jimmunol.org/content/192/11/5245 References This article cites 56 articles, 31 of which you can access for free at: http://www.jimmunol.org/content/192/11/5245.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 30, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2014 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Structural and Functional Correlates of Enhanced Antiviral Immunity Generated by Heteroclitic CD8 T Cell Epitopes Jonathan A. Trujillo,*,1 Stephanie Gras,†,1 Kelly-Anne Twist,† Nathan P.
    [Show full text]
  • Epitope Similarity Cannot Explain the Pre-Formed T Cell Immunity
    www.nature.com/scientificreports OPEN Epitope similarity cannot explain the pre‑formed T cell immunity towards structural SARS‑CoV‑2 proteins Ulrik Stervbo 1,2,4*, Sven Rahmann 3,4*, Toralf Roch 1,2, Timm H. Westhof1 & Nina Babel1,2 The current pandemic is caused by the SARS‑CoV‑2 virus and large progress in understanding the pathology of the virus has been made since its emergence in late 2019. Several reports indicate short lasting immunity against endemic coronaviruses, which contrasts studies showing that biobanked venous blood contains T cells reactive to SARS‑CoV‑2 S‑protein even before the outbreak in Wuhan. This suggests a preformed T cell memory towards structural proteins in individuals not exposed to SARS‑CoV‑2. Given the similarity of SARS‑CoV‑2 to other members of the Coronaviridae family, the endemic coronaviruses appear likely candidates to generate this T cell memory. However, given the apparent poor immunological memory created by the endemic coronaviruses, immunity against other common pathogens might ofer an alternative explanation. Here, we utilize a combination of epitope prediction and similarity to common human pathogens to identify potential sources of the SARS‑CoV‑2 T cell memory. Although beta‑coronaviruses are the most likely candidates to explain the pre‑existing SARS‑CoV‑2 reactive T cells in uninfected individuals, the SARS‑CoV‑2 epitopes with the highest similarity to those from beta‑coronaviruses are confned to replication associated proteins—not the host interacting S‑protein. Thus, our study suggests that the observed SARS‑CoV‑2 pre‑formed immunity to structural proteins is not driven by near‑identical epitopes.
    [Show full text]
  • Exploring Epitope and Functional Diversity of Anti-SARS-Cov2 Antibodies Using AI-Based Methods
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.23.424199; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Exploring epitope and functional diversity of anti-SARS-CoV2 antibodies using AI-based methods. Dumet C1., Jullian Y.1, Musnier A.1, Rivière Ph.2, Poirier N.3, Watier H.4, Bourquard T.1, Poupon A.1,5,* 1: MAbSilico SAS, 1 impasse du Palais, 37000 Tours, France. 2: VisionsCarto, France. 3: OSE Immunotherapeutics, Nantes, France. 4: EA7501, Université de Tours, et laboratoire d'immunologie, CHU de Tours. 5: PRC, INRAE, CNRS, Université de Tours, 37380 Nouzilly, France ; Inria, Inria Saclay-Île-de-France, 91120 Palaiseau, France *: corresponding author. Summary Since the beginning of the COVID19 pandemics, an unprecedented research effort has been conducted to analyze the antibody responses in patients, and many trials based on passive immunotherapy — notably monoclonal antibodies — are ongoing. Twenty-one antibodies have entered clinical trials, 6 having reached phase 2/3, phase 3 or having received emergency authorization. These represent only the tip of the iceberg, since many more antibodies have been discovered and represent opportunities either for diagnosis purposes or as drug candidates. The main problem facing laboratories willing to develop such antibodies is the huge task of analyzing them and choosing the best candidate for exhaustive experimental validation. In this work we show how artificial intelligence-based methods can help in analyzing large sets of antibodies in order to determine in a few hours the best candidates in few hours.
    [Show full text]